KRAS assays from FFPE
Wednesday 7 December 2011
Activating mutations of the BRAF and KRAS genes cause constitutive stimulation of an important cell-signaling pathway promoting tumorigenesis, and are increasingly recognized as determinants of response to targeted cancer therapies.
The frequency of KRAS mutations is about 32%, with G>A transitions at position 2 of codons 12 and 13 being most prevalent.
Implementation of novel pyrosequencing assays to screen for common mutations of BRAF and KRAS in a cohort of sporadic colorectal cancers. Packham D, Ward RL, Ap Lin V, Hawkins NJ, Hitchins MP. Diagn Mol Pathol. 2009 Jun;18(2):62-71. PMID: 19430299